BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28419079)

  • 1. Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Tran WT; Gangeh MJ; Sannachi L; Chin L; Watkins E; Bruni SG; Rastegar RF; Curpen B; Trudeau M; Gandhi S; Yaffe M; Slodkowska E; Childs C; Sadeghi-Naini A; Czarnota GJ
    Br J Cancer; 2017 May; 116(10):1329-1339. PubMed ID: 28419079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A priori prediction of tumour response to neoadjuvant chemotherapy in breast cancer patients using quantitative CT and machine learning.
    Moghadas-Dastjerdi H; Sha-E-Tallat HR; Sannachi L; Sadeghi-Naini A; Czarnota GJ
    Sci Rep; 2020 Jul; 10(1):10936. PubMed ID: 32616912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications.
    Goldberg H; Zandbank J; Kent V; Leonov-Polak M; Livoff A; Chernihovsky A; Guindy M; Evron E
    Eur J Surg Oncol; 2017 Aug; 43(8):1415-1420. PubMed ID: 28526187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection of chemotherapy-refractory patients by monitoring textural alterations in diffuse optical spectroscopic images.
    Sadeghi-Naini A; Vorauer E; Chin L; Falou O; Tran WT; Wright FC; Gandhi S; Yaffe MJ; Czarnota GJ
    Med Phys; 2015 Nov; 42(11):6130-46. PubMed ID: 26520706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
    Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
    Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
    Tozaki M; Uno S; Kobayashi T; Aiba K; Yoshida K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Kawakami M; Fukuda K
    Radiat Med; 2004; 22(4):246-53. PubMed ID: 15468945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer.
    Yu YH; Zhu X; Mo QG; Cui Y
    Clin Transl Oncol; 2018 Apr; 20(4):524-533. PubMed ID: 28921461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
    Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy?
    Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD
    Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.
    Mukai H; Arihiro K; Shimizu C; Masuda N; Miyagi Y; Yamaguchi T; Yoshida T
    Breast Cancer; 2016 Jan; 23(1):73-77. PubMed ID: 26423822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
    Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
    Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging.
    Yoon HJ; Kim Y; Chung J; Kim BS
    Breast J; 2019 May; 25(3):373-380. PubMed ID: 29602210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
    O'Toole SA; Spillane C; Huang Y; Fitzgerald MC; Ffrench B; Mohamed B; Ward M; Gallagher M; Kelly T; O'Brien C; Ruttle C; Bogdanska A; Martin C; Mullen D; Connolly E; McGarrigle SA; Kennedy J; O'Leary JJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):571-580. PubMed ID: 32378053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi-institutional study.
    DiCenzo D; Quiaoit K; Fatima K; Bhardwaj D; Sannachi L; Gangeh M; Sadeghi-Naini A; Dasgupta A; Kolios MC; Trudeau M; Gandhi S; Eisen A; Wright F; Look Hong N; Sahgal A; Stanisz G; Brezden C; Dinniwell R; Tran WT; Yang W; Curpen B; Czarnota GJ
    Cancer Med; 2020 Aug; 9(16):5798-5806. PubMed ID: 32602222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.